SCHEMBL14859659

SCHEMBL14859659

CC(C)(C)c1ccc(C(=O)N(S)C(=O)Nc2cccc3c(O)cccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ PABPC1 P11940 1/20 0.46
▸ EIF4H Q15056 1/20 0.46
▸ RAB9A P51151 3/20 0.44
▸ DHPS P49366 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ TRPV1 Q8NER1 2/20 0.43
▸ PSD A5PKW4 1/20 0.42
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14859168 0.87 NLRP3 (0.53) MEN1KMT2APABPC1EIF4HRAB9A
SCHEMBL14859806 0.84 TRPV1 (0.49) MEN1KMT2APABPC1EIF4HRAB9A
SCHEMBL14860018 0.82 TRPV1 (0.52) MEN1KMT2ARAB9AKDM4ETRPV1
SCHEMBL14859552 0.82 MEN1 (0.71) MEN1KMT2APABPC1EIF4HSMN1; SMN2
SCHEMBL14859767 0.80 TRPV1 (0.43) MEN1KMT2APABPC1EIF4HRAB9A
SCHEMBL14859296 0.79 NR1H4 (0.54) MEN1KMT2ARAB9ASMN1; SMN2TRPV1
SCHEMBL14859134 0.79 NR1H4 (0.47) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL14859880 0.78 RAB9A (0.54) MEN1KMT2APABPC1EIF4HRAB9A
SCHEMBL14859574 0.76 HDAC6 (0.52) MEN1KMT2APABPC1EIF4HRAB9A
SCHEMBL14859608 0.76 L3MBTL1 (0.48) MEN1KMT2ADHPSSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP claimed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US claimed
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP disclosed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT UGP2, TPMT, UPP1 MEN1 4110/4885KMT2A 2604/4885PABPC1 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback